查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023年至2028年痤瘡治療市場預測
市場調查報告書
商品編碼
1410017

2023年至2028年痤瘡治療市場預測

Acne Treatment Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

痤瘡治療市場預計將從2021年的188,107,000美元成長到2028年的244,810,000美元，複合年成長率為3.84%。

當毛囊被皮脂和死皮細胞堵塞時，就會出現痤瘡。結果就是粉刺、黑頭和白斑。痤瘡可以發生在任何年齡，但最常見於青少年。痤瘡盛行率的增加以及青少年人口的增加是痤瘡治療市場的主要成長促進因素。

全球痤瘡盛行率不斷上升

由於生活方式改變、遺傳和不規律的日常生活等因素，痤瘡盛行率不斷增加，這是痤瘡治療市場的主要成長要素。根據 IHME 的數據，2019 年尋常性痤瘡影響了約 496 萬人，並導致傷殘調整生命年 (DALY)，其中 352 萬人發生在 15 歲至 49 歲的老年人中。此外，成人痤瘡的增加表明需要治療，從而推動痤瘡治療市場的發展。

青少年人口增加

阻塞和痤瘡爆發的主要原因是年齡，青少年和年輕人更容易患痤瘡。世界青少年人口的增加導致痤瘡增多，這表明痤瘡治療市場在未來幾年將擴大。根據聯合國兒童基金會預測，2022年4月，全球青少年人口將達到13億，幾乎佔全球總人口的16%。根據約翰霍普金斯的說法，女孩的這種情況通常比男孩發生得更早，通常在青春期開始時發生。在大多數情況下，痤瘡會消失，但大約 12% 的女性和 3% 的男性可能在 40 多歲時仍然有痤瘡。此外，痤瘡也會導致人的情緒和心理問題。青少年數量的不斷增加，加上痤瘡對心理的嚴重影響，預計將推動痤瘡治療市場的規模擴大。

技術進步和相關計劃

技術的進步正在幫助開發增強型痤瘡治療方法，從而推動痤瘡治療市場的發展。根據美容外科論壇教員的說法，基於能量的設備幾乎總是加速癒合過程，這對於不想等待標準的 8 到 12 週結果的痤瘡患者來說至關重要。此外，其他相關措施也進一步推動了痤瘡治療市場的發展。例如，不列顛哥倫比亞省的醫療保健系統於 2023 年 6 月推出了一個網站，並開始預約藥劑師治療痤瘡等小病。

市場機會

痤瘡問題的盛行率上升以及青少年人口的增加正在迅速推動痤瘡治療市場的成長。此外，痤瘡問題也源自於不良的飲食習慣、不良的衛生習慣、不講衛生的情況，這在成年人中也普遍存在。例如，疾病預防控制中心估計，2 歲至 19 歲之間，十分之五的成年人和十分之六的兒童定期飲用一種或多種含糖飲料。這些痤瘡高發生率的因素進一步為進入痤瘡治療市場提供了巨大的機會。

市場抑制因素

除了所有的成長要素之外，痤瘡治療的一些副作用預計將限制痤瘡治療市場的成長。局部痤瘡藥物的常見副作用是暫時乾燥和發炎。內服藥物可能會產生更嚴重的副作用，例如抗生素引起的消化不良和頭暈。此外，痤瘡藥物會增加服用避孕藥的女性出現血栓和高血壓的風險。口服異維A酸（一種用於治療嚴重痤瘡的藥物）可能會出現嚴重的副作用，特別是如果您在服用異維A酸期間懷孕了。有報導稱，懷孕期間使用異維A酸的母親所生的嬰兒會出現嚴重的先天缺陷。

預計北美在預測期內將經歷高速成長

預計在預測期內，北美將佔據痤瘡治療市場的重要佔有率。這一市場佔有率歸因於痤瘡治療的高採用率以及大量患有痤瘡的人。例如，根據 AADA 的數據，每年約有 5,000 萬美國患有痤瘡，使其成為美國最常見的皮膚病。 AADA 估計，大約 85% 12 至 24 歲之間的人至少患有輕度痤瘡。此外，Obagi、Skinmedica 和 Colorescience 等主要市場參與者的產品推出和供應，為痤瘡治療市場的成長做出了重大貢獻。

市場主要發展

2022年9月，理膚泉推出了專門針對成人痤瘡的全新Effaclar水楊酸痤瘡治療精華液。三重酸複合配方，含有乙醇酸、​​脂羥酸和 1.5% 水楊酸，可清除痤瘡疤痕並有助於預防未來的痘痘。 2022年7月，Glenmark首次在印度推出用於治療中重度痤瘡的外用米諾環素4%凝膠。該凝膠適合 9 歲及以上兒童，與其他外用抗菌製劑相比，具有最低的 MIC90。 2021年11月，Sun Pharma開發的新型痤瘡治療霜Winlevi在美國市場上市。 Winlevi 霜適合 12 歲及以上人群，也是過去 40 年來第一個獲得 FDA核准的痤瘡治療藥物，具有First-in-Class的作用機制。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表

第2章調查方法

  • 調查資料
  • 先決條件

第3章執行摘要

  • 研究亮點

第4章市場動態

  • 市場促進因素
  • 市場抑制因素
  • 波特五力分析
  • 產業價值鏈分析

第5章痤瘡治療市場：依產品

  • 介紹
  • 類視色素A
  • 抗生素
  • 異維A酸
  • 其他

第6章痤瘡治療市場：依給藥途徑

  • 介紹
  • 口服
  • 熱帶

第7章痤瘡治療市場：按分銷管道

  • 介紹
  • 醫院藥房
  • 零售及網路藥局

第8章痤瘡治療市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 其他
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作

第10章 公司簡介

  • PHYTOMER
  • Skin Medica
  • PCA
  • Obaji
  • Colorescience
  • Revision Skincare
  • Sente
  • Jan Marini Skin Research
  • Botanix Pharmaceuticals
簡介目錄
Product Code: KSI061615654

The acne treatment market is expected to grow at a CAGR of 3.84% from US$188.107 million in 2021 to US$244.81 million in 2028.

When hair follicles become clogged with oil and dead skin cells, acne is a skin disorder that develops. It results in pimples, blackheads, or whiteheads. Although it can afflict anyone at any age, acne is most prevalent in teenagers. The growing prevalence of acne along with the rising adolescent population are the primary growth drivers of the acne treatment market.

Growing Prevalence of Acne Globally

The growing prevalence of acne due to factors such as changing lifestyles, genetics, and untimely routine is a major growth factor in the acne treatment market. According to the IHME, around 4.96 million people had acne vulgaris causing Disability-adjusted life year (DALY) in 2019 out of which, 3.52 million occurred in people aged between 15-49 years old. Moreover, acne in adults is increasing indicating the need for treatment thereby propelling the acne treatment market. According to the American Academy of Dermatology Association (AADA), around 15% of women are affected with acne annually which further widens the acne treatment market size as women are expected to be more image-conscious.

Rising Adolescent Population

The major cause of clogging and acne development is age as teenagers and younger adults are more affected by the acne. The rising global adolescent population causing more acne is indicating the acne treatment market expansion in the coming years. According to UNICEF, there were 1.3 billion adolescents worldwide in April 2022 making up almost 16% of the total world population. According to Jon Hopkins, Girls are typically affected earlier than boys, and it usually starts around the beginning of puberty. In most cases, acne is outgrown, although about 12% of women and 3% of men may still have acne in their 40s. Moreover, acne may cause emotional and psychological problems in a person. The growing teenage population along with the severe emotional impact of acne is contemplated to bolster the acne treatment market size.

Technological Advancements and Related Programs

The advances in technology are helping in the development of enhanced acne treatments which is propelling the acne treatment market. According to Cosmetic Surgery Forum Faculty members, Energy-based devices nearly always expedite the healing process, which is crucial for acne sufferers who don't want to wait the standard eight to 12 weeks for results. Additionally, other related efforts are further boosting the acne treatment market. For instance, the British Columbia Health Care system launched a website in June 2023 to book appointments with pharmacists for the treatment of minor ailments including acne.

Opportunities in the Market

The growing prevalence of acne problems along with the rising adolescent population is rapidly aiding the acne treatment market growth thereby providing an opportunity for market players to enhance the customer experience. Moreover, the problem of acne also happens from bad diet, poor hygiene, and sanitation which are also prevailing in adults. For instance, 5 out of 10 adults and 6 out of 10 children between the ages of 2 and 19 regularly consume one or more sugary beverages as per the CDC estimates. These factors causing the higher prevalence of acne further provide a phenomenal opportunity to enter the acne treatment market.

Restraints in the Market

Apart from all the growth factors, a few side effects of acne treatments are expected to limit the acne treatment market growth. The common side effects of topical acne drugs are dryness and irritation which are temporary. The more serious side effects can occur in the case of oral medications such as indigestion, or dizziness caused by antibiotics. Moreover, acne treatment medications can increase the risk of blood clots and high blood pressure in women taking birth control pills. Serious side effects from oral isotretinoin (a drug for severe acne) are possible, particularly if you become pregnant while taking it. According to reports, babies born to mothers who used isotretinoin during pregnancy had serious birth defects.

North America is Expected To Grow at a High Rate During The Forecast Period

North America is expected to hold a significant share of the acne treatment market during the forecast period. The factors attributed to such a share are a huge number of acne-affected people along with higher adoption of acne treatments. For instance, nearly 50 million Americans are affected with acne annually and it is the most common prevailing skin condition in the US as per the AADA. The estimates of the AADA suggest that around 85% of people get affected with at least minor acne and are aged between 12-24 years. Moreover, the presence of major market players such as Obagi, Skinmedica, and Colorescience further contributes significantly to the acne treatment market growth through product launches and easy accessibility.

Acne Treatment Market Players

  • Sente, founded in 2007 is helping physicians to address uneven skin concerns through several clinical tests. Medical experts have long employed therapeutically developed heparan sulfate analog (HSA) by the company to support the body's inflammatory healing process.
  • Obagi, a US-based transformative skincare company is serving the population for the last 35 years providing solutions for all skin types and tones. The company provides acne solutions through its Clenziderm Therapeutic lotion, Obagi 360 Retinol 1.0, Obagi Clinical Retinol 0.5 Retexturizing Cream, and Obagi 360 Retinol 0.5.
  • Revision Skincare offers disruptive skincare innovation with a mission to deliver benefits through products that patients can see. The company provides solutions to numerous skin concerns including loss of firmness, aging eyes, wrinkles, hyperpigmentation, fatigued skin, and acne.

Key Market Developments

  • In September 2022, a new Effaclar Salicyclic Acid Acne Treatment Serum was launched by La Roche Posay to specifically target adult acne. Effaclar Serum's Triple Acid Complex formula, which combines glycolic acid, lipo-hydroxy acid, and 1.5% salicylic acid, clears acne scars while assisting in the prevention of future outbreaks.
  • In July 2022, the first topical Minocycline 4% gel for the treatment of moderate to severe acne was introduced by Glenmark in India. This gel is suitable for people aged 9 years or above and compared to other topical antibacterial formulations available, it offers the lowest MIC90.
  • In November 2021, a new acne treatment cream Winlevi developed by Sun Pharma was launched in the US market. The Winlevi cream is suitable for people aged 12 years and above and it was also the first FDA-approved acne drug with a first-in-class mechanism in the last 40 years.

Segmentation:

By Product

  • Retinoids
  • Antibiotics
  • Isotretinoin
  • Others

By Route of Administration

  • Oral
  • Tropical

By Distribution Channel

  • Hospital Pharmacies
  • Retail & Online Pharmacies

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. ACNE TREATMENT MARKET BY PRODUCT

  • 5.1. Introduction
  • 5.2. Retinoids
  • 5.3. Antibiotics
  • 5.4. Isotretinoin
  • 5.5. Others

6. ACNE TREATMENT MARKET BY ROUTE OF ADMINISTRATION

  • 6.1. Introduction
  • 6.2. Oral
  • 6.3. Tropical

7. ACNE TREATMENT MARKET BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Retail & Online Pharmacies

8. ACNE TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. PHYTOMER
  • 10.2. Skin Medica
  • 10.3. PCA
  • 10.4. Obaji
  • 10.5. Colorescience
  • 10.6. Revision Skincare
  • 10.7. Sente
  • 10.8. Jan Marini Skin Research
  • 10.9. Botanix Pharmaceuticals